Form 8-K - Current report:
SEC Accession No. 0001193125-25-141112
Filing Date
2025-06-16
Accepted
2025-06-16 07:55:26
Documents
15
Period of Report
2025-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d19535d8k.htm   iXBRL 8-K 57591
2 EX-2.1 d19535dex21.htm EX-2.1 566770
3 EX-99.1 d19535dex991.htm EX-99.1 38491
7 GRAPHIC g19535dsp_9.jpg GRAPHIC 3402
  Complete submission text file 0001193125-25-141112.txt   937382

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sage-20250613.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20250613_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20250613_pre.xml EX-101.PRE 10810
17 EXTRACTED XBRL INSTANCE DOCUMENT d19535d8k_htm.xml XML 3504
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 251048558
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)